Scheduling the adjuvant endocrine therapy for early stage breast cancer

被引:2
作者
Kahruman, Sera [1 ]
Ulusal, Elif [1 ]
Butenko, Sergiy [1 ]
Hicks, Illya V. [2 ]
Diehl, Kathleen M. [3 ]
机构
[1] Texas A&M Univ, Dept Ind & Syst Engn, College Stn, TX 77843 USA
[2] Rice Univ, Houston, TX 77005 USA
[3] Univ Michigan Hlth Syst, Ann Arbor, MI 48109 USA
关键词
Breast cancer; Adjuvant endocrine therapy; Scheduling; Mathematical programming; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; OPTIMIZATION APPROACH; TAMOXIFEN THERAPY; CHEMOTHERAPY; LETROZOLE; EXEMESTANE; ARIMIDEX; MODEL;
D O I
10.1007/s10479-010-0741-y
中图分类号
C93 [管理学]; O22 [运筹学];
学科分类号
070105 ; 12 ; 1201 ; 1202 ; 120202 ;
摘要
Based on the data available through published trial results, we build a mixed integer nonlinear programming (MINLP) model in order to find an optimal treatment plan for a given HR+ early stage breast cancer patient who is postmenopausal. The objective is to maximize the disease-free survival percentage at the end of the treatment period subject to the constraints on the risk of contralateral breast cancer and the risks of several side effects, including endometrial cancer, thromboembolic events, cardiovascular diseases, bone fractures, hot flushes, and vaginal bleeding. The results of numerical experiments suggest the effectiveness of some of the schedules currently used in practice, as well as suggest some attractive alternative treatment plans.
引用
收藏
页码:683 / 705
页数:23
相关论文
共 30 条
  • [1] Optimizing chemotherapy scheduling using local search heuristics
    Agur, Zvia
    Hassin, Refael
    Levy, Sigal
    [J]. OPERATIONS RESEARCH, 2006, 54 (05) : 829 - 846
  • [2] *AM CANC SOC, 2009, CANC REF INF
  • [3] ATAC Trialist Group, 2004, LANCET, V364, P1
  • [4] Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model
    Barbolosi, D
    Iliadis, A
    [J]. COMPUTERS IN BIOLOGY AND MEDICINE, 2001, 31 (03) : 157 - 172
  • [5] Beil DR, 2001, IMA J MATH APPL MED, V18, P343
  • [6] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
    Bergman, L
    Beelen, MLR
    Gallee, MPW
    Hollema, H
    Benraadt, J
    van Leeuwen, FE
    [J]. LANCET, 2000, 356 (9233) : 881 - 887
  • [7] Boccardo F., 2005, LANCET, V366, P455
  • [8] Individualizing cancer treatment: Biological optimization models in treatment planning and delivery
    Brahme, A
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (02): : 327 - 337
  • [9] Buzdar A. U., 2005, AROMATASE INHIBITORS
  • [10] Clarke M, 1998, LANCET, V351, P1451